e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Management of airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term follow-up of patients under omalizumab initiated during the pre-approval period in France
M. Molimard, P. Chanez, C. Pison, L. Tétu, V. Le Gros (Marseille, Grenoble, Toulouse, Rueil-Malmaison, France)
Source:
Annual Congress 2010 - Management of airway disease
Session:
Management of airway disease
Session type:
Thematic Poster Session
Number:
4562
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Molimard, P. Chanez, C. Pison, L. Tétu, V. Le Gros (Marseille, Grenoble, Toulouse, Rueil-Malmaison, France). Long-term follow-up of patients under omalizumab initiated during the pre-approval period in France. Eur Respir J 2010; 36: Suppl. 54, 4562
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Clinical outcome in patients treated with omalizumab during pre-approval period in France
Source: Eur Respir J 2007; 30: Suppl. 51, 621s
Year: 2007
Long-term prognosis in rehabilitated COPD patients. A 3-year controlled study and a 3-year follow-up
Source: Eur Respir J 2001; 18: Suppl. 33, 224s
Year: 2001
Participation in scheduled asthma follow-up contacts and adherence to treatment during 12-year follow-up
Source: Virtual Congress 2021 – Primary care organisation and epidemiology
Year: 2021
Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
One-year follow-up of asthma patients in a randomised controlled trial of high-intensity training. Are there lasting effects?
Source: International Congress 2018 – Clinical markers of asthma
Year: 2018
A ten year follow-up of former paediatric asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 233s
Year: 2005
The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial
Source: ERJ Open Res, 5 (2) 00032-2019; 10.1183/23120541.00032-2019
Year: 2019
A multicenter randomized trial for the effectiveness of structured discharge and follow-up protocol on readmission rate in COPD patients receiving LTOT/NIV: one-year interim analysis.
Source: International Congress 2018 – Hot topics in non-invasive ventilation
Year: 2018
Two-years of a community maintenance follow-up program in patients with COPD
Source: Annual Congress 2012 - The latest insights in pulmonary rehabilitation
Year: 2012
Long-term benefits of pulmonary rehabilitation in COPD patients: 2 year follow-up
Source: International Congress 2017 – Novel treatments for rehabilitation of patients with chronic respiratory diseases
Year: 2017
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study
Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020
Year: 2021
A longitudinal follow-up of severe asthma patients receiving reslizumab
Source: International Congress 2017 – Asthma management
Year: 2017
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
COPD patients under 50 years of age: 4-year follow-up in the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Our clinical experience in surgical therapy of 272 patients with bronchiectasis during 15-year period
Source: Annual Congress 2008 - Pleuropulmonary infections; thoracic trauma
Year: 2008
The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study
Source: Eur Respir J 2006; 28: Suppl. 50, 439s
Year: 2006
Stability of FENO50 in a COPD cohort in Sweden over 2-year follow-up
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Long-term effectiveness of surgery treatment of TB patients
Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept